These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

242 related articles for article (PubMed ID: 33858507)

  • 1. Arsenic trioxide synergistically promotes the antileukaemic activity of venetoclax by downregulating Mcl-1 in acute myeloid leukaemia cells.
    Cho H; Jang JE; Eom JI; Jeung HK; Chung H; Kim JS; Cheong JW; Min YH
    Exp Hematol Oncol; 2021 Apr; 10(1):28. PubMed ID: 33858507
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Arsenic Trioxide and Venetoclax Synergize against AML Progenitors by ROS Induction and Inhibition of Nrf2 Activation.
    Hoang DH; Buettner R; Valerio M; Ghoda L; Zhang B; Kuo YH; Rosen ST; Burnett J; Marcucci G; Pullarkat V; Nguyen LXT
    Int J Mol Sci; 2022 Jun; 23(12):. PubMed ID: 35743010
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Synergistic killing effects of homoharringtonine and arsenic trioxide on acute myeloid leukemia stem cells and the underlying mechanisms.
    Tan M; Zhang Q; Yuan X; Chen Y; Wu Y
    J Exp Clin Cancer Res; 2019 Jul; 38(1):308. PubMed ID: 31307525
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Superior anti-tumor activity of the MDM2 antagonist idasanutlin and the Bcl-2 inhibitor venetoclax in p53 wild-type acute myeloid leukemia models.
    Lehmann C; Friess T; Birzele F; Kiialainen A; Dangl M
    J Hematol Oncol; 2016 Jun; 9(1):50. PubMed ID: 27353420
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Oridonin Synergistically Enhances the Pro-Apoptotic Effect of Venetoclax on Acute Myeloid Leukemia Cells by Inhibiting AKT Signaling.
    Chen L; Li D; Guo X; Cheng C; Wei X
    Front Biosci (Landmark Ed); 2023 Sep; 28(9):195. PubMed ID: 37796705
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Artesunate improves venetoclax plus cytarabine AML cell targeting by regulating the Noxa/Bim/Mcl-1/p-Chk1 axis.
    Zhang J; Wang Y; Yin C; Gong P; Zhang Z; Zhao L; Waxman S; Jing Y
    Cell Death Dis; 2022 Apr; 13(4):379. PubMed ID: 35443722
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Genetic biomarkers predict response to dual BCL-2 and MCL-1 targeting in acute myeloid leukaemia cells.
    Grundy M; Balakrishnan S; Fox M; Seedhouse CH; Russell NH
    Oncotarget; 2018 Dec; 9(102):37777-37789. PubMed ID: 30701031
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cotargeting BCL-2 and PI3K Induces BAX-Dependent Mitochondrial Apoptosis in AML Cells.
    Rahmani M; Nkwocha J; Hawkins E; Pei X; Parker RE; Kmieciak M; Leverson JD; Sampath D; Ferreira-Gonzalez A; Grant S
    Cancer Res; 2018 Jun; 78(11):3075-3086. PubMed ID: 29559471
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Inhibition of Bcl-2 Synergistically Enhances the Antileukemic Activity of Midostaurin and Gilteritinib in Preclinical Models of FLT3-Mutated Acute Myeloid Leukemia.
    Ma J; Zhao S; Qiao X; Knight T; Edwards H; Polin L; Kushner J; Dzinic SH; White K; Wang G; Zhao L; Lin H; Wang Y; Taub JW; Ge Y
    Clin Cancer Res; 2019 Nov; 25(22):6815-6826. PubMed ID: 31320594
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The pan-Bcl2 Inhibitor AT101 Activates the Intrinsic Apoptotic Pathway and Causes DNA Damage in Acute Myeloid Leukemia Stem-Like Cells.
    Zhang L; Zhou Y; Chen K; Shi P; Li Y; Deng M; Jiang Z; Wang X; Li P; Xu B
    Target Oncol; 2017 Oct; 12(5):677-687. PubMed ID: 28710745
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Inhibition of CK2{alpha} and PI3K/Akt synergistically induces apoptosis of CD34+CD38- leukaemia cells while sparing haematopoietic stem cells.
    Cheong JW; Min YH; Eom JI; Kim SJ; Jeung HK; Kim JS
    Anticancer Res; 2010 Nov; 30(11):4625-34. PubMed ID: 21115916
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Venetoclax Synergistically Enhances the Anti-leukemic Activity of Vosaroxin Against Acute Myeloid Leukemia Cells Ex Vivo.
    Liu F; Knight T; Su Y; Edwards H; Wang G; Wang Y; Taub JW; Lin H; Sun L; Ge Y
    Target Oncol; 2019 Jun; 14(3):351-364. PubMed ID: 31115744
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Synergistic effect of chidamide and venetoclax on apoptosis in acute myeloid leukemia cells and its mechanism.
    Li G; Li D; Yuan F; Cheng C; Chen L; Wei X
    Ann Transl Med; 2021 Oct; 9(20):1575. PubMed ID: 34790781
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A novel Mcl-1 inhibitor synergizes with venetoclax to induce apoptosis in cancer cells.
    Zhao T; He Q; Xie S; Zhan H; Jiang C; Lin S; Liu F; Wang C; Chen G; Zeng H
    Mol Med; 2023 Jan; 29(1):10. PubMed ID: 36658493
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Combined venetoclax and alvocidib in acute myeloid leukemia.
    Bogenberger J; Whatcott C; Hansen N; Delman D; Shi CX; Kim W; Haws H; Soh K; Lee YS; Peterson P; Siddiqui-Jain A; Weitman S; Stewart K; Bearss D; Mesa R; Warner S; Tibes R
    Oncotarget; 2017 Dec; 8(63):107206-107222. PubMed ID: 29291023
    [TBL] [Abstract][Full Text] [Related]  

  • 16. BCL-2 inhibitor synergizes with PI3Kδ inhibitor and overcomes FLT3 inhibitor resistance in acute myeloid leukaemia.
    Yao MY; Wang YF; Zhao Y; Ling LJ; He Y; Wen J; Zheng MY; Jiang HL; Xie CY
    Am J Cancer Res; 2022; 12(8):3829-3842. PubMed ID: 36119822
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Venetoclax enhances DNA damage induced by XPO1 inhibitors: A novel mechanism underlying the synergistic antileukaemic effect in acute myeloid leukaemia.
    Yu H; Wu S; Liu S; Li X; Gai Y; Lin H; Wang Y; Edwards H; Ge Y; Wang G
    J Cell Mol Med; 2022 May; 26(9):2646-2657. PubMed ID: 35355406
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Synergistic efficacy of homoharringtonine and venetoclax on acute myeloid leukemia cells and the underlying mechanisms.
    Yuan F; Li D; Li G; Cheng C; Wei X
    Ann Transl Med; 2022 Apr; 10(8):490. PubMed ID: 35571387
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Bone marrow stroma-induced resistance of chronic lymphocytic leukemia cells to arsenic trioxide involves Mcl-1 upregulation and is overcome by inhibiting the PI3Kδ or PKCβ signaling pathways.
    Amigo-Jiménez I; Bailón E; Aguilera-Montilla N; Terol MJ; García-Marco JA; García-Pardo A
    Oncotarget; 2015 Dec; 6(42):44832-48. PubMed ID: 26540567
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Abemaciclib drives the therapeutic differentiation of acute myeloid leukaemia stem cells.
    Xie X; Zhang W; Zhou X; Ye Z; Wang H; Qiu Y; Pan Y; Hu Y; Li L; Chen Z; Yang W; Lu Y; Zou S; Li Y; Bai X
    Br J Haematol; 2023 Jun; 201(5):940-953. PubMed ID: 36916190
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.